|
- Phase 2 clinical trial results show potential to shorten TB . . .
In 2012, bedaquiline was approved for drug-resistant TB treatment, making it the first new antibiotic to be approved in decades However, recent years have seen a rise in strains of TB that are
- Phase 2 data suggest new drug could unlock shorter TB treatment
An international team of investigators today announced promising data from a trial of a novel antibiotic that could potentially shorten and simplify treatment for tuberculosis (TB) patients The interim data from the phase 2 trial, released yesterday at the Union World Conference on Lung Health in
- New drug could be a breakthrough in treatment for killer TB . . .
Sorfequiline, a new antibiotic, showed stronger action against the deadly bacteria than existing treatments, with a comparable safety profile, researchers from the TB Alliance told the Union Conference on Lung Health in Copenhagen on Wednesday
- New clinical trial shows promise for shorter TB treatment
New clinical trial results presented by TB Alliance at the Union World Conference on Lung Health show that the novel antibiotic candidate sorfequiline (TBAJ-876), a next-generation diarylquinoline
- New TB Trial Data Shows Sorfequiline Could Dramatically . . .
A major breakthrough in tuberculosis (TB) drug development is emerging New phase 2 clinical trial results presented by TB Alliance at the Union World Conference on Lung Health indicate that sorfequiline (TBA-876) — a next-generation diarylquinoline antibiotic — could significantly improve and shorten TB treatment when used in the
- Can New Drug Herald Shorter TB Treatment? - Medscape
Clinical trial results found that a new antibiotic candidate could shorten TB treatment from the standard 6 months to 8 weeks
- New Antibiotic Sorfequiline Shows Promise in Cutting TB . . .
Sorfequiline (TBAJ-876) outperformed the conventional four-drug regimen of isoniazid, rifampin, pyrazinamide and ethambutol Researchers also reported that it showed higher activity than treatment combinations using bedaquiline — the first approved next-generation diarylquinoline, introduced in 2012 for multidrug-resistant TB
|
|
|